한빛사논문
- 조회386
Han Ah Lee1, Yeon Seok Seo1, and Seung Up Kim2,3,*
1Department of Internal Medicine, Institute of Gastroenterology, Korea University College of Medicine, Seoul Korea;
2Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul Korea;
3Yonsei Liver Center, Severance Hospital, Seoul, Korea
*Corresponding author
Abstract
To the editor
We read with great interest the article entitled “Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV Infection in China” (1). In this study by Yip et al. (1), the authors concluded that tenofovir disoproxil fumarate (TDF) was associated with a significantly lower risk of hepatocellular carcinoma (HCC) development than entecavir (ETV) in treatment-naïve Chinese patients with chronic hepatitis B (CHB). The main findings of this study seem to be consistent with a previous study by Choi et al. (2), but are completely inconsistent with the results of several recent studies, including ours, showing no long-term differences, including the risk of developing HCC, between treatment-naïve patients with CHB treated with ETV vs. TDF (3-5). Several issues should be kept in mind when interpreting the results of the study (1).
논문정보
- Correspondence
- 2020년 06월 (BRIC 등록일 2021-08-05)
- 국내 연구진
- 의약학 > 응용의학
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
